Allylescaline

Allylescaline
Chemical Nomenclature
Common names	Allylescaline, AL
Substitutive name	4-allyloxy-3,5-dimethoxyphenethylamine
Systematic name	4-Allyloxy-3,5-dimethoxyphenethylamine
Class Membership
Psychoactive class	Psychedelic
Chemical class	Phenethylamine
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Oral Dosage Threshold 15 mg Light 20 - 30 mg Common 30 - 40 mg Strong 40 - 60 mg Heavy 60 mg + Duration Total 8 - 12 hours Onset 45 - 240 minutes DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions

Summary sheet: Allylescaline

4-Allyloxy-3,5-dimethoxyphenethylamine (also known as allylescaline) is a lesser-known novel psychedelic substance of the phenethylamine class. It is a structural analog of mescaline and related to escaline and methallylescaline. It is relatively uncommon and has little to no history of human usage.

The effects of this compound were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story. He lists the dosage range as 20 – 35 mg orally and describes the duration of action to be 8 - 12 hours.

Very little data exists about the pharmacological properties, metabolism, and toxicity of allylescaline. It is highly advised to use harm reduction practices if using this substance.

Chemistry

Allylescaline, or 4-allyloxy-3,5-dimethoxyphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino -NH2 group through an ethyl chain. Escaline contains two methoxy functional groups CH₃O- which are attached to carbons R₃, and R₅ and an additional allyloxy group at carbon R₄ of the phenyl ring. Allylescaline is the 4-allyloxy analog of mescaline.

Allylescaline, also referred to as 4-allyloxy-3,5-dimethoxyphenethylamine, is research compounds that is not well-known. The IUPAC name for Allylescaline is 4-Allyloxy-3,5-dimethoxyphenethylamine 4-Allyloxy-3,5-dimethoxy-1-ethylami with the molecular formula being C13H19NO3 and a molecular weight of 237.29 g/mol. Allylescaline is known to have an average mass of 237.294998 Da and a monoisotopic mass of 237.136002 Da.

Pharmacology

Further information: Serotonergic psychedelic

Allylescaline acts as a 5-HT_2A partial agonist. The psychedelic effects are believed to come from allylescaline's efficacy at the 5-HT_2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

It is the 4O-allyl homolog of mescaline, and binds similarly to the serotonin receptors. It seems to have considerably increased potency by weight, with an active dose in humans reported to be 20-40 mg (compared to 300-400 mg for mescaline).

It is relatively uncommon and has little to no history of human usage. Very little data exists about the pharmacological properties, metabolism, and toxicity of allylescaline. The effects of this compound were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story.

Subjective effects

This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

• • Spontaneous tactile sensations
  • Increased heart rate
  • Nausea
  • Pupil dilation

Visual effects

• Enhancements

  • Colour enhancement
  • Pattern recognition enhancement
  • Visual acuity enhancement

  Distortions

  • Drifting (melting, breathing, morphing and flowing)
  • Colour shifting
  • Depth perception distortions
  • Perspective distortions
  • Symmetrical texture repetition
  • Tracers
  • After images
  • Brightness alteration
  • Diffraction

  Geometry

  Hallucinatory states

  • Transformations
  • Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)

Cognitive effects

• • Conceptual thinking
  • Cognitive euphoria
  • Delusion
  • Emotion enhancement
  • Immersion enhancement
  • Increased music appreciation
  • Memory suppression
    • Ego death
  • Novelty enhancement
  • Personal bias suppression
  • Thought loops
  • Time distortion
  • Unity and interconnectedness

Auditory effects

• • Enhancements
  • Distortions
  • Hallucinations

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

• Erowid Experience Vaults: Allylescaline

Toxicity and harm potential

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational allylescaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because allylescaline is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried allylescaline suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

Allylescaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of allylescaline is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Allylescaline presents cross-tolerance with all psychedelics, meaning that after the consumption of allylescaline all psychedelics will have a reduced effect.

Legal issues

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• Germany: Allylescaline is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of February 1, 1997 (called "4-Allyloxy-3,5-dimethoxy-phenethylazan"). It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
• Japan: Allylescaline is a controlled substance in Japan effective March 25th, 2015.
• Sweden: Allylescaline is illegal in Sweden as of January 2016.
• Switzerland: Allylescaline is a controlled substance specifically named under Verzeichnis E.
• United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.

See also

• Responsible use
• Mescaline
• Phenethylamine
• Hallucinogen

External links

• Allylescaline (Wikipedia)
• Allylescaline (PiHKAL / Isomer Design)